BIO-key International, Inc. (BKYI) AI Stock Analysis

BIO-key International, Inc. specializes in the development and distribution of fingerprint identification biometric technology and software solutions for commercial enterprises, government agencies, and educational institutions worldwide. The company offers BIO-key PortalGuard and PortalGuard IDaaS, which deliver cloud-based identity management and user authentication across cloud and on-premises applications. Its portfolio also includes BIO-key VST, WEB-key, and Civil and Large-Scale ID Infrastructure solutions. Additionally, BIO-key sells hardware fingerprint scanners under the SideSwipe, EcoID, and SidePass brand names. Originally founded in 1993 as SAC Technologies, the company rebranded to BIO-key International, Inc. in 2002.

BIO-key delivered a 5-year revenue compound annual growth rate of 16.5% from FY2020 to FY2025. Annual revenue expanded from $5.1M in FY2021 to $7.0M in FY2022 and $7.8M in FY2023. Revenue subsequently fell 10.6% in FY2024 to $6.9M and dropped 12.0% in FY2025 to $6.1M. Gross margin fluctuated sharply, recording 67.3% in FY2021, 18.5% in FY2023, and 77.5% in FY2025. Net income remained in deficit throughout the period, registering -$5.1M in FY2021, -$11.9M in FY2022, -$8.5M in FY2023, -$4.3M in FY2024, and -$4.6M in FY2025. In the latest quarter ended June 30, 2026, revenue increased 13.1% year-over-year, bringing trailing twelve months revenue to $6.7M with a profit margin of -90.1%.

As of June 30, 2026, BIO-key held $1.4M in cash and short-term investments against total debt of $149,732, producing net cash of $1.2M. The company had shareholders' equity of $4.3M, total assets of $7.5M, a current ratio of 1.26, and a debt-to-equity ratio of 0.03. Cash flow from operations was -$4.7M in FY2025, and free cash flow was -$4.7M. For FY2025, capital expenditures totaled $12,012, while the company's share count declined 86.8% over the trailing 5-year period.

BIO-key has a market capitalization of $5.4M and an enterprise value of $3.0M. The stock trades at a price-to-sales multiple of 0.8x and an EV-to-revenue multiple of 0.5x, below the 1.5x price-to-sales median of its US-listed Industrials peers. Its price-to-book ratio is 0.8x. In the market, BIO-key's share price fell 64.0% over the trailing one-year period and dropped 99.5% over five years, underperforming the S&P 500 benchmark gains of 16.8% and 83.0% over the same respective timeframes.

Wall Street coverage includes 1 Buy rating, with 0 Strong Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $20.00, compared to the last close of $2.63 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$1.62 and revenue of $9.0M. For the following fiscal year, 1 analyst projects revenue of $12.0M, reflecting 33.3% revenue growth, and positive EPS of $0.22. BIO-key beat EPS estimates in 2 of the trailing 4 quarters, with its next earnings report scheduled for November 13, 2026.

This page is an AI-written research summary of BIO-key International, Inc. (BKYI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BKYI income statement, BKYI balance sheet, BKYI key metrics, BKYI analyst forecast, BKYI chart. See the BKYI stock overview for the latest quote and news.